Yousif Capital Management LLC Boosts Stake in Moderna, Inc. $MRNA

Yousif Capital Management LLC increased its position in Moderna, Inc. (NASDAQ:MRNA) by 6.9% in the 2nd quarter, Holdings Channel reports. The firm owned 44,856 shares of the company’s stock after buying an additional 2,888 shares during the period. Yousif Capital Management LLC’s holdings in Moderna were worth $1,238,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. GAMMA Investing LLC increased its position in Moderna by 149.8% in the 1st quarter. GAMMA Investing LLC now owns 7,926 shares of the company’s stock valued at $225,000 after acquiring an additional 4,753 shares during the period. Janney Montgomery Scott LLC increased its position in Moderna by 37.1% in the 1st quarter. Janney Montgomery Scott LLC now owns 13,825 shares of the company’s stock valued at $392,000 after acquiring an additional 3,744 shares during the period. QRG Capital Management Inc. increased its position in Moderna by 16.1% in the 1st quarter. QRG Capital Management Inc. now owns 8,274 shares of the company’s stock valued at $235,000 after acquiring an additional 1,150 shares during the period. Praxis Investment Management Inc. increased its position in Moderna by 110.5% in the 1st quarter. Praxis Investment Management Inc. now owns 16,710 shares of the company’s stock valued at $474,000 after acquiring an additional 8,770 shares during the period. Finally, Kentucky Retirement Systems Insurance Trust Fund acquired a new position in Moderna in the 1st quarter valued at about $266,000. 75.33% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

MRNA has been the topic of several recent research reports. Morgan Stanley boosted their price target on Moderna from $31.00 to $32.00 and gave the company an “equal weight” rating in a research report on Friday, October 10th. Barclays dropped their price target on Moderna from $40.00 to $31.00 and set an “equal weight” rating on the stock in a research report on Monday, August 4th. Weiss Ratings restated a “sell (e+)” rating on shares of Moderna in a research report on Wednesday, October 8th. Citigroup assumed coverage on Moderna in a research report on Friday, August 1st. They issued a “neutral” rating and a $40.00 price target on the stock. Finally, Leerink Partners dropped their target price on Moderna from $18.00 to $15.00 and set an “underperform” rating on the stock in a research report on Friday, August 22nd. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, twelve have given a Hold rating and five have assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $39.93.

Moderna Price Performance

Shares of NASDAQ:MRNA opened at $27.24 on Tuesday. The business’s 50 day simple moving average is $25.94 and its 200-day simple moving average is $27.11. The firm has a market capitalization of $10.64 billion, a price-to-earnings ratio of -3.62 and a beta of 2.01. Moderna, Inc. has a 12 month low of $23.15 and a 12 month high of $57.69.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Friday, August 1st. The company reported ($2.13) EPS for the quarter, topping the consensus estimate of ($2.99) by $0.86. The business had revenue of $142.00 million for the quarter, compared to analyst estimates of $116.26 million. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The company’s quarterly revenue was down 41.1% on a year-over-year basis. During the same quarter in the previous year, the company earned ($3.33) EPS. Moderna has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that Moderna, Inc. will post -9.61 earnings per share for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.